Cough and fever in a female with Crohn's disease receiving infliximab

European Respiratory Journal

Volumn 26, Issue 2, 2005, Pages 354-357

  Stratakos, G ^a   Kalomenidis, I ^a   Papas, V ^a   Malagari, K ^a   Kollintza, A ^a   Roussos, C ^a   Anagnostopoulou, M ^b   Paniara, O ^b   Zakynthinos, S ^a   Papiris, S A ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; INFLIXIMAB; MEROPENEM; METHYLPREDNISOLONE; VORICONAZOLE;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CROHN DISEASE; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FIBEROPTIC BRONCHOSCOPY; HEPATITIS B; HUMAN; HYPERTENSION; HYSTERECTOMY; LABORATORY DIAGNOSIS; LIVER INJURY; LUNG INFECTION; LUNG LAVAGE; NOCARDIA ASTEROIDES; NON INSULIN DEPENDENT DIABETES MELLITUS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SERODIAGNOSIS; THRUSH; URINARY TRACT INFECTION;

AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; NOCARDIA ASTEROIDES; NOCARDIA INFECTIONS; PNEUMOCYSTIS JIROVECI; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS;

EID: 23144449975     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00005205     Document Type: Article

References (12)

1. Rutgeerts P, Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610.
2. Derkx B, Taminiau J, Radema S, et al. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-174.
3. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21: Suppl. 2, s24-s34.
4. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320-334.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
6. van der Klooster JM, Bosman RJ, Oudemans van Straaten HM, van Spoel Ji, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29: 2327-2329.
7. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am J Respir Crit Care Med 2003; 167: 1279-1282.
8. Kroesen S, Widmer AF, Tyndal A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under ant-TNF-α therapy. Rheumatology 2003; 42: 617-621.
9. Russian DA, Levine SJ. Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci 2001; 321: 56-65.
10. Silva CL, Faccioli LH. Tumor necrosis factor and macrophage activation are important in clearance of Nocardia brasiliensis from the livers and spleens of mice. Infect Immunol 1992; 60: 3566-3570.
11. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor-α and γ interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60: 1279-1284.
12. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Waish TJ. Guidelines for treatment of Candidiasis. CID 2004; 38: 161-189.